ホーム/ABT

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze ABT in workspace
ABTNYSE/health care

Abbott Laboratories

$92.11Down-1,82 (-1,94%)
Research reviewed: 2026年7月12日 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Abbott Laboratories operates in Health Care Equipment within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Eröffnung
93,95
Hoch
94,00
Tief
91,64
Marktkapitalisierung
160,44 Mrd.
KGV
25.80
52-Wochen-Hoch
--
Dividende
2.680%
Quartalsdividende
--

3-month price context

直近3か月の推移を表示し、フル調査ワークスペースに進む前に短期構造を把握できます。

Investment thesis

Base case
Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine. The base case remains conditional on nutrition weakness staying manageable.
Bull case
Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine. The Exact Sciences acquisition establishes a meaningful oncology-diagnostics platform and adds long-term growth opportunities in cancer screening and precision diagnostics. Continued growth in key emerging markets can provide a diversified contribution from established branded generics.
Bear case
Nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals. The large Exact Sciences transaction introduces integration, financing, dilution, and execution risks before projected strategic benefits are realized. Ongoing preterm infant formula litigation creates uncertain legal costs and potential reputational pressure for the nutrition business.
Thesis invalidation
Reassess the thesis if nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals.

Key catalysts

  • Medical devices growth

    Broad growth across Abbott's medical-device portfolio, including diabetes care and structural heart, can remain the company's primary organic growth engine.

  • Oncology diagnostics expansion

    The Exact Sciences acquisition establishes a meaningful oncology-diagnostics platform and adds long-term growth opportunities in cancer screening and precision diagnostics.

  • Established pharmaceuticals growth

    Continued growth in key emerging markets can provide a diversified contribution from established branded generics.

Principal risks

  • Nutrition weakness

    Nutrition sales declined in the quarter, and persistent weakness could offset strength in medical devices and established pharmaceuticals.

  • Exact Sciences integration

    The large Exact Sciences transaction introduces integration, financing, dilution, and execution risks before projected strategic benefits are realized.

  • Infant-formula litigation

    Ongoing preterm infant formula litigation creates uncertain legal costs and potential reputational pressure for the nutrition business.

Latest earnings research

2026 Q1

For the quarter ended March 31, 2026, Abbott reported sales growth led by medical devices, established pharmaceuticals, and diagnostics, while nutrition declined; management updated its full-year outlook to include the completed Exact Sciences acquisition.

Valuation interpretation

  • Sustained medical-device growth and successful oncology-diagnostics expansion can support a diversified health-care quality premium.
  • Nutrition weakness and the scale of Exact Sciences integration warrant a discount until acquired growth and financial synergies become visible.

Peer research

BSXISRGSYK

Recent news

24/7 Wall St. · vor 5 Stunden

Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?

Zacks · vor 13 Stunden

Unlocking Q2 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics

MedTech Dive · vor 15 Stunden

Freenome colorectal cancer test data improve on earlier results

Insider Monkey · vor 17 Stunden

Baird Initiates Coverage on Abbott Laboratories (ABT) Stock with Outperform Rating

Simply Wall St. · vorgestern

Does Libre 3 Plus Integration Expand Tandem’s Interoperability Edge And Bull Case For TNDM?

Motley Fool · vorgestern

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

Data and research sources

Research updated: 2026年7月12日 00:00 UTC
3 verified sources
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact SciencesAbbott Laboratories · earningsVerified

Fetched: 2026/7/12 0:00:00 UTC

Published: 2026/4/16 0:00:00

Open original source
Abbott Investor RelationsAbbott Laboratories · companyVerified

Fetched: 2026/7/12 0:00:00 UTC

Open original source
Abbott Form 10-Q for the Quarter Ended March 31, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 2026/7/12 0:00:00 UTC

Open original source

Continue in the research workspace

Keep ABT in context, run a multi-agent analysis, and monitor thesis changes.

Analyze ABT free

リサーチシステム全体を見る

各段階には固有の役割があり、次の段階で検証可能な成果を残します。

リサーチ手法市場レポートを読む銘柄を探す

Continue researching this stock

市場アナリスト

市場アナリスト は コアリサーチ の中で 観察 段階を専門に担い、後続判断の前提を整える役割です。

ファンダメンタルズアナリスト

ファンダメンタルズアナリスト は コアリサーチ の中で 観察 段階を専門に担い、後続判断の前提を整える役割です。

ニュースアナリスト

ニュースアナリスト は コアリサーチ の中で 観察 段階を専門に担い、後続判断の前提を整える役割です。

リスクマネージャー

リスクマネージャー は リスクと監視 の中で 監視 段階を専門に担い、後続判断の前提を整える役割です。